OpenAI and the FDA are reportedly discussing AI for drug evaluations

Openai met with the authorities from the US Department of Food and Drug, and discussed the use of EU to speed up the drug assessments of the EU, The string reported Wednesday.

According to the report, Openai and FDA discussed a project called Cergpt, which looks like a AI vehicle for the Center for Drug Assessment (CDE). CDE, meter and recipe medications, Associates, one of the United States escape, was reported to be part of the talks.

It is not uncommon to take more than ten years to complete drug development processes. Openai’s work with FDA aims to speed up a small part of this graph, until the end. AI began a long time as a potential speed that can be used throughout the drug developmentMake some notorious slow steps more efficient. He said that there are answers to how to control the insecurity of AI models.